Ginkgo Bioworks Holdings Inc [DNA] stock prices are down -3.61% to $8.01 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DNA shares have gain 26.74% over the last week, with a monthly amount drifted -13.96%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Ginkgo Bioworks Holdings Inc [NYSE: DNA] stock has seen the most recent analyst activity on May 15, 2024, when BTIG Research downgraded its rating to a Sell. Previously, William Blair downgraded its rating to Underperform on May 10, 2024. On November 14, 2023, downgrade downgraded it’s rating to Mkt Perform and revised its price target to $2.50 on the stock. BTIG Research downgraded its rating to a Neutral. Goldman downgraded its rating to a Sell and reduced its price target to $1.25 on June 02, 2023. William Blair downgraded its rating to Mkt Perform for this stock on May 11, 2023. In a note dated November 29, 2022, Berenberg initiated an Buy rating and provided a target price of $6 on this stock.
The stock price of Ginkgo Bioworks Holdings Inc [DNA] has been fluctuating between $5.26 and $82.80 over the past year. Currently, Wall Street analysts expect the stock to reach $7.34 within the next 12 months. Ginkgo Bioworks Holdings Inc [NYSE: DNA] shares were valued at $8.01 at the most recent close of the market. An investor can expect a potential drop of -8.36% based on the average DNA price forecast.
Analyzing the DNA fundamentals
The Ginkgo Bioworks Holdings Inc [NYSE:DNA] reported sales of 184.34M for trailing twelve months, representing a drop of -30.24%. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at -4.07%, Pretax Profit Margin comes in at -4.87%, and Net Profit Margin reading is -4.87%. To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -0.86 and Total Capital is -0.51. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.54.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.67 points at the first support level, and at 7.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.42, and for the 2nd resistance point, it is at 8.83.
Ratios To Look Out For
It’s worth pointing out that Ginkgo Bioworks Holdings Inc [NYSE:DNA]’s Current Ratio is 4.71. Also, the Quick Ratio is 4.71, while the Cash Ratio stands at 4.41. Considering the valuation of this stock, the price to sales ratio is 2.28, the price to book ratio is 0.47.
Transactions by insiders
Recent insider trading involved Che Austin, Officer, that happened on Sep 20 ’24 when 99.0 shares were purchased. Officer, Che Austin completed a deal on Sep 19 ’24 to buy 99.0 shares. Meanwhile, Officer Che Austin bought 99.0 shares on Sep 18 ’24.
